Locate providers:   

Restylane and Perlane Now Available in a Low-Pain Option

 

Facial fillers are making the move to adding local anesthetic to their formulas, and they're available now.

Medicis, stock symbol MRX, announced today that they have started shipping their newly FDA approved fillers {!RESTYLANE-L | RESTYLANE} and {!PERLANE-L | PERLANE}. In January of this year, the U.S. Food and Drug Administration (FDA) approved RESTYLANE-L(TM) for implantation into the mid to deep dermis, and PERLANE-L(TM) for implantation into the deep dermis to superficial subcutis, both for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds.

restylane-L
Model Photo


It's only been two weeks since the announcement of their approval and Medicis is already putting this new low pain option into physicians' hands. The new formulation includes lidocaine, a local anesthetic which numbs the treatment area in seconds. Many who've had dental work done are familiar with lidocaine, it is one of the most commonly used local anesthetics. Many physicians were already mixing lidocaine with their fillers to improve patient comfort, but is now FDA approved and available ready-made.

Earlier this year, Juvederm, another popular facial filler option, released Juvederm XC- also with lidocaine. Juvederm was the third filler available, after Prevelle and Hylaform.

Consumers now are trying to get the most bang for their buck and having a filler option that removes the pain factor is sure to be a boost to Medicis' bottom line. Patients are opting for less and less invasive procedures that keep them out of the doctors office or recovery room and back to work as soon as possible. Fillers can be performed during a lunch hour and allow the patient to go back to their life immediately.

Restylane, Perlane, and Juvederm all use hyaluronic acid (HA) to plump out wrinkles and make patients look years younger. HA is a water attractant, meaning that water molecules bond with it, so that overtime, even more improvement will appear.